Gene Editing Breakthrough Makes Cancer-Fighting T Cells More Powerful and Long-Lasting

CAR-T cell therapy represents one of the most promising cancer treatments, but its effectiveness is often limited by poor T cell persistence and declining function over time. This study addresses these critical limitations through a novel gene editing approach.

Researchers conducted a comprehensive base-editing screen of PIK3CD, a gene encoding PI3K delta, which plays crucial roles in T cell metabolism, function, and survival. They systematically tested various point mutations to identify optimal genetic modifications for different CAR designs.

The methodology involved creating libraries of genetically modified CAR-T cells with different PIK3CD mutations, then testing their performance in laboratory models and animal studies. The team compared two major CAR designs: 4-1BBz and CD28z costimulatory domains, analyzing cellular metabolism, proliferation, memory formation, and anti-tumor efficacy.

Key findings revealed that optimal genetic modifications depend on CAR design. For 4-1BBz CARs, the E81K mutation increased PI3K signaling, enhancing proliferation, metabolic fitness, and long-term persistence. Conversely, 28z CARs benefited from the L32P mutation, which reduced PI3K signaling and improved memory T cell formation. Both modifications significantly enhanced therapeutic efficacy in animal models.

This research has profound implications for cancer treatment and potentially broader longevity applications. Enhanced CAR-T cells could provide more durable cancer remissions, reducing treatment failures and improving patient outcomes. The precision gene editing approach could extend to other immune cell therapies, potentially enhancing immune system function against age-related diseases and cancers that increase with aging. However, this remains early-stage research requiring extensive clinical validation before human application.